Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...
AbbVie (NYSE:ABBV) and its shareholders were dealt a major setback Monday morning after results from a late-stage trial on ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
2don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
David Risinger’s rating is based on several key considerations surrounding AbbVie’s recent clinical trial outcomes. The company’s announcement on November 11, 2024, revealed that emraclidine’s ...
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late-stage trials. The market ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback